Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in North Carolina

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Legal Concerns

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context has empowered individuals to make informed decisions about their well-being, often by distilling complex biomedical data into accessible knowledge. Within this broad framework, discussions of bone health and osteoporosis management have been routine, with emphasis on maintaining skeletal integrity through lifestyle measures and pharmacological interventions. The transition from this general health heritage to a more specific occupational exposure concern requires a shift in focus from population-level wellness to individual risk factors that may arise from therapeutic choices. In particular, the use of bisphosphonate medications such as Fosamax has been associated with rare but serious adverse events, including osteonecrosis of the jaw. This condition, while uncommon, raises important questions about the intersection of medical treatment and legal accountability. As patients and healthcare providers navigate these complexities, the role of legal counsel becomes relevant for those who have experienced harm. In North Carolina, the statute of limitations imposes strict timeframes for filing claims related to such injuries. Thus, the general health context naturally pivots to a focused examination of Fosamax exposure, the risk of osteonecrosis of the jaw, and the legal considerations for affected individuals seeking recourse.

Understanding Fosamax and Its Medical Risks

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms of ONJ after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare, as noted in a study where fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years after either three or five years of prescription, and the incidence of ONJ was rare (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Legal Considerations for Fosamax-Related ONJ in North Carolina

From a medical risk perspective, patients taking Fosamax should be aware of the potential for ONJ, especially if they have risk factors such as dental procedures or poor oral hygiene. The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information, which includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, patients may not always receive or understand these warnings, which can affect their ability to make informed decisions about treatment and to recognize early symptoms. For affected patients in North Carolina, attorney-related considerations are important. The statute of limitations for filing a lawsuit related to Fosamax and ONJ in North Carolina is typically governed by state law, which generally allows a certain period from the date of injury or discovery of the injury to file a claim. Patients should consult with a qualified attorney to understand the specific time limits that apply to their case, as these can vary based on individual circumstances and legal interpretations. The timeline between exposure to Fosamax and documented harm is critical, as ONJ can develop months after starting the drug, and symptoms may not appear until after dental procedures or infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This delay can complicate the determination of when the statute of limitations begins to run. In summary, Fosamax is associated with a rare but serious risk of ONJ, with known risk factors including dental procedures and duration of use. Patients should be vigilant about oral health and discuss any concerns with their healthcare provider. Legal considerations, including the statute of limitations in North Carolina, require prompt action and consultation with an attorney to preserve potential claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in North Carolina?

The statute of limitations for filing a lawsuit related to Fosamax and osteonecrosis of the jaw in North Carolina is typically governed by state law, which generally allows a certain period from the date of injury or discovery of the injury to file a claim. Because ONJ can develop months after starting Fosamax, the timeline can be complex. It is crucial to consult with a qualified attorney promptly to understand the specific time limits that apply to your case.

What are the known risk factors for developing osteonecrosis of the jaw from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.